Bio Screening Industry News

(Amherst, NH) - The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and - ultimately - pharmaceutical marketers.

Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.

Compliance with drug therapy and disease management protocols has been and is a primary concern within the healthcare and pharmaceutical industries. Efforts to enhance compliance are having a non-negligible effect on drug formulations and delivery decisions, and can be a significant factor in the prescribing decisions of most physicians. Compliance concerns have driven and continue to drive investment in new drug delivery technologies.

As patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that new drug product success no longer only depends on the medication itself but also on achieving a patient-friendly form of application.

New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Reusable injectors designed to accept prefilled syringes or drug cartridges will improve ease-of-use and increase alternative device share of the growing self-injection market. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.

These findings are contained in a comprehensive report, Injectable Drug Delivery: Evolving Markets, Emerging Opportunities. More information is available at www.greystoneassociates.org .

About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

These drug patents will expire in June 2007

Drug Tradename Applicant Company Generic Drug Name Patent Number Patent Expiration
————————————————————————————————–
AEROBID Roche Palo flunisolide 4,933,168 JUN 12,2007
ANTHELIOS SX Loreal Usa avobenzone; ecamsule; octocrylene 4,585,597 JUN 16,2007
ESTRING Pharmacia And Upjohn estradiol 4,871,543 JUN 12,2007
ESTRING Pharmacia And Upjohn estradiol 5,188,835 JUN 12,2007
IMITREX Glaxosmithkline sumatriptan 4,816,470 JUN 28,2007
IMITREX Glaxosmithkline sumatriptan succinate 4,816,470 JUN 28,2007
IMITREX STATDOSE Glaxosmithkline sumatriptan succinate 4,816,470 JUN 28,2007
LAMISIL Novartis terbinafine 4,755,534 JUN 30,2007
LAMISIL Novartis terbinafine hydrochloride 4,755,534 JUN 30,2007
LAMISIL AT Novartis terbinafine hydrochloride 4,755,534 JUN 30,2007
MAVIK Abbott trandolapril 4,933,361 JUN 12,2007
NASALIDE Ivax Res flunisolide 4,933,168 JUN 12,2007
NASAREL Ivax Res flunisolide 4,933,168 JUN 12,2007
PAXIL Glaxosmithkline paroxetine hydrochloride 4,721,723 JUN 29,2007
PAXIL CR Glaxosmithkline paroxetine hydrochloride 4,721,723 JUN 29,2007
PHOTOFRIN Axcan Scandipharm porfimer sodium 4,932,934 JUN 12,2007
TARKA Abbott trandolapril; verapamil hydrochloride 4,933,361 JUN 12,2007
THALITONE Monarch Pharms chlorthalidone 4,933,360 JUN 12,2007
VERELAN Elan Drug verapamil hydrochloride 4,863,742 JUN 19,2007
VERELAN PM Elan Drug verapamil hydrochloride 4,863,742 JUN 19,2007

Source: DrugPatentWatch.com

The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio

Barcelona, Spain | May 30, 2007 | The Business Intelligence firm La Merie S.L. reported today that the US$ 9.6 bln market of the two blockbuster antithrombotic agents enoxaparin and clopidogrel is going to be rearranged by loss of patent protection and emergence of phase III stage competitors with improved profiles. While Bristol-Myers Squibb already suffers from dropping sales (US$ 3.3 bln in 2006 for clopidogrel), Sanofi-Aventis will be affected stronger in its ex-US sales of clopidogrel (US$ 3 bln) and global sales of enoxaparin (3.3 bln). Sanofi-Aventis has the biggest anticoagulant pipeline by numbers, but does not lead the next generation of oral thrombin (factor IIa) and factor Xa inhibitors which have the potential to replace parenteral product enoxaparin, a low molecular weight heparin (LMWH). At least seven clinical stage direct thrombin inhibitors and at least 10 clinical stage direct factor Xa inhibitors are in the anticoagulant pipeline lead by Boehringer Ingelheim and Bayer Schering Pharma. Despite the larger market of the antiplatelet agent prasugrel, the number of advanced clinical stage antiplatelet projects is smaller than that of anticoagulants. These results and more were found in a competitor analysis conducted by La Merie Business Intelligence. The competitor analysis of Antithrombotics can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.

The competitor analysis evaluated anticoagulant and antiplatelet agents in development. Apart from the oral direct factor IIa and Xa inhibitors, oral heparin and oral LMWH developments are ongoing and novel targets being explored in preclinical and clinical trials. Further companies with a strong antithrombotics portfolio include Daiichi-Sankyo, AstraZeneca and Organon & Schering-Plough. The convenience of oral administration will be the most obvious advante of the next generation anticoagulants, but the reduced incidence of thrombotic events and of bleeding side effects key to the commercial success under the light of the imminent approval of the first enoxaparin generics.

About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
About PipelineReview.com
Pipelinereview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. A free R&D Newletter conveniently brings via e-mail a daily selection of the most interesting news from biopharmaceutical R&D. For more information visit pipelinereview.com

LONDON, May 1 /PRNewswire/ — Pharmaprojects, the world’s leading source of business-critical intelligence on drugs in global R&D reveals that after a period of levelling off in recent years in the growth of the number of drugs in development, a new era of pipeline expansion may have begun. Pharmaprojects’ unique ‘Trends Search’ facility, which recently published its new data for 2007, shows a palpable increase in the number of drugs in R&D this year (see Graph 1 above)

As the above graph shows, there had been a period from 2004-2006 of relatively slow growth in the number of drug candidates being pursued, when compared to significant increases seen in the early part of the decade. There had been fears in some sectors that this lack of growth might have signalled a permanent change in the pharmaceutical industry’s fortunes and could even have signified a point at which growth might go into reverse. Hopefully however, this newest figure could represent the beginning of a brighter phase.

Pharmaprojects’ data shows that at this time last year there were just less than 400 fewer products under development within the industry, which considering the cost of bringing drugs through the development process, represents an increased investment of many millions of pounds. Pharmaprojects’ trends search also allows one to drill down into this information further and assess how this overall increase in drug development is reflected in the various stages of the R&D process (see Graph 2 above)

Perhaps the most encouraging result of this further analysis is that this increase is not ascribable to a large rise in the number of preclinical compounds, as is often the case, but that the largest increases are in the clinical stages of drug development. As preclinical compounds stand a relatively low chance of making it to the market, a larger increase here does not necessarily represent a particularly positive trend. However, once a compound makes it past the screening process to enter clinical trials, the possibility of it successfully reaching the market increases dramatically with each further stage achieved.

On a more cautionary note, one should remember not to jump the gun with such analyses. As Ian Lloyd, Managing Editor of Pharmaprojects, states, “One year’s worth of promising data does not mean an end to the industry’s woes. Trends by their very nature only emerge after a number of years, making next year’s figures crucial in determining whether we are seeing a sustained recovery or whether 2007 is merely a blip”. Nonetheless, any positive trend must begin somewhere, and this year’s data makes for encouraging reading indeed.

About Pharmaprojects

Pharmaprojects, the leading database tracking global pharmaceutical development from early preclinical study through to launch or discontinuation, has 27 years’ experience as an information provider to the industry. Pharmaprojects uses a fully-searchable application that allows you to pinpoint the specific information you are looking for, whether it be comprehensive drug profiles, a competitor’s pipeline or licensing opportunities.

About Pharmaprojects’ Trend Analysis

Pharmaprojects provides the unique and unparalleled ability to view trends in the pharmaceutical industry by taking a ’snapshot’ of the database every year since 1995, allowing subscribers to compare year-on-year data across a variety of searchable criteria including drug status, originators, countries, therapies, pharmacologies and more. All data and diagrams contained within this press release are taken directly from Pharmaprojects.

Pharmaprojects is available weekly on the Web and monthly via CD-ROM format. Further details on this story as well as a wealth of information including recent conferences, companies and drug targets are all available in Pharmaprojects’ Update Analysis newsletter. This, as well as a forum of other free information regarding pharmaceutical R&D pipeline intelligence and demo requests for Pharmaprojects, can be found at http://www.pharmaprojects.com

New Report by Applied Data Research Analyzes the Impact on Drug Development Timelines

(Nashua, NH) – As the availability of new tools for automating the drug discovery process identifies potential drug candidates at an accelerating rate, the formulation limitations of a majority of these new NCEs is creating a bottleneck in preclinical development. Drug developers are responding by exploring drug formulation technologies – often proprietary processes offered by third parties – to negotiate their way past critical steps in the path to commercializing new chemical entities and driving the financial success of their companies.

Much of the current focus in formulation science is concerned with processes that can improve the solubility of APIs. The importance of solubilization technologies is also underscored by the capability they bestow on formulators attempting to re-formulate approved drugs approaching the end of their patent life.

Issues surrounding water insolubility of active compounds have important business and market implications for new drug development. This impact goes beyond potential future drug therapeutics, effectively limiting reformulation strategies for existing products at a time when extending the market life of proprietary drugs through derivative formulations has become a key business strategy.

Drug formulation technology companies are working with drug developers at pharmaceutical companies to help define the prescription formulations that will enter preclinical development and the clinical trial pipeline in the coming months and years. New formulation capabilities will expand the number of new NCEs that can be formulated to meet pharmacochemical thresholds.

More information is available at www.applieddata.org .

About Applied Data

Applied Data Research is a drug therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Contact:

Greg Stone

Voice: 603-595-6225

Fax: 603-804-0466

www.applieddata.org

Source: Applied Data Research

DUBLIN, Ireland–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/reports/c48935 ) has announced the addition of Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery to their offering.

This report reviews, analyzes and sizes the cell based screening and analysis market. The study uncovers interesting information about key equipment, consumables, reagents, software and services that are marketed to biotech and pharmaceutical companies that are doing drug discovery research.

Large bio-pharma companies have commented at industry meetings that fifty percent of their high throughput compound screening projects in drug discovery involves screening cells. The companies are using cell-based assays for both primary and secondary screening and have taken a great interest in the areas of high content screening and high content analysis.

The report assesses the market and maps the competitors on the market landscape with more than 80 companies identified. The financial section sizes the market and discusses the five-year revenue projection. The market is segmented by major product areas as well as market sub segments. This market is also segmented by major world regions to see the growth or how the market share might change.

Major company alliances, M&As, patents that were issued during the last two years are reviewed and analyzed. Large data tables summarize the alliances, M&As and patents. The alliance table summarizes more than 210 deals. The patent table displays key details of over 340 patents.

This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. More than 42 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like.

This report includes 28 company profiles that provide the reader a snapshot of the companies’ focus or activities. The provided Internet links help readers access companies’ own web sites for further review.

Topics Covered
1.        What Cell Analysis is and What We Are Aiming for With This
Research Project
1.1       Our Definition of the Cell Analysis Market
1.2       The Aim of This Research Report

2.        Overview -- Current Market Status and R&D Status in Biotech
and Pharma (Bio-Pharma) for Cell Analysis
2.1       Cell Based Screening & Analysis Helps Pharma Productivity
2.1.1     Drug Making Productivity
2.1.2     Increasing Use of Cell Based Screening and Analysis
Platforms
2.2       Cell-Based Analysis Applications in Bio-Pharma Drug
Discovery & Development
2.2.1     Traditional Pharma Drug Discovery Paradigm & Compound
Screening
2.2.2     Drug Targets and Main Drug Target Classes
2.2.3     Cell Assay Development - Bio-pharmas Make Their Own Assays
2.2.4     High Throughput Screening (HTS) & High Content Screening
(HCS)
2.2.5     Toxicology Testing (Safety Screening)
2.3       Current Equipment & Tools and R&D for Cell Analysis
2.4       Current Technologies and Related R&D for Cell Based
Screening-Analysis
2.5       Current Reagents & Assays and Related R&D for Cell Based
Screening-Analysis
2.6       Main Competitors by Large, Medium and Start-up
(Emerging Companies)

3.        Trends and Directions of Cell Based Screening and Analysis
Equipment and Technologies
3.1       Trends: Cell Screening Equipment
3.1.1     Plate Imaging Equipment for Cell based HTS
3.1.2     Imaging Cytometry Equipment for HCS/ HCA
3.1.3     Emerging Developments In Cell Based Screening
3.2       Trends: Cell Screening Technologies
3.2.1     Labeling Reagents and No-Wash Assays
3.2.2     Cells as Reagents
3.2.3     Stem Cells Used as a Drug Discovery Tool

4.        Alliances & IP
4.1       Summary and Review of Major M&As, Alliances, or Deals
4.1.1     M&A and Alliances at a Glance
4.1.2     Leading M&A Acquirers
4.1.3     Data Tables for M&As and Alliances Involving Cell-Based
Analysis
4.2       Summary of Key Patent IP Involving Cell-Based Analysis

5.        Market Size and Forecast 2006 to 2011
5.1       The Total Worldwide Cell-Based Screening-Analysis Market
Size
5.2       Market Segments by Product Type and Revenues
5.2.1     Major Market Segments by Main Product Areas
5.2.2     Comparison of Major Market Segments by Market Shares,
2007& 2011
5.2.3     Equipment Segment by Product Type
5.2.4     'Consumables' Segment by Product Type
5.2.5     Content Segment by Product Type
5.2.6     Services Segment by Product Type
5.2.7     'Others' Segment by Product Type
5.3       Market Segments By Major Worldwide Regions
5.3.1     Region Segments
5.3.2     Comparison of Region Segments by Market Shares, 2007 & 2011
5.4       Outlook for Leading Commercial Vendors Market Share Rank

6.        Activities of Cell Based Screening-Analysis Companies
6.1       Multiplatform Cell Screening/Analysis Systems
6.1.1 to 6.1.7 Total 7 companies
6.2       Flow Cytometry Screening Systems
6.2.1 to 6.2.4 Total 4 companies
6.3       High Content Screening/Analysis Cell Imaging Systems
6.3.1 to 6.3.5 Total 5 companies
6.4       Cell-Based Screening Assays/Reagents
6.4.1 to 6.4.5 Total 5 companies
6.5       Cell Screening Assays/Reagents
6.5.1 to 6.5.3 Total 3 companies
6.6       Contract Research and Development Services
6.6.1 to 6.6.3 Total 3 companies
6.7       Cell Screening/Analysis Software
6.7.1 to 6.7.4 Total 4 companies

7.        Conclusions: Findings & Opportunities
7.1       Important Findings
7.1.1     Market Size and Growth
7.1.2     Alliances and IP
7.1.3     Bio-Pharma Product & Technology Users
7.1.4     Equipment
7.1.5     Services
7.2       The Cell-Based Screening & Analysis Business/ Tech Market
Roadmap and Opportunities
7.2.1     Major CBSA Products & Services Segments by Growth Rate
7.2.2     Important Growth Areas Within Major Segments

8.        Appendix
8.1       Company Contacts    (Total 85 companies)
8.2       Patent Data Tables  (Total 340 patents)

List of Tables

List of Illustrations

For more information visit http://www.researchandmarkets.com/reports/c48935

DUBLIN, Ireland–(BUSINESS WIRE)–Aug 24, 2006 - Research and Markets (http://www.researchandmarkets.com/reports/c41023) has announced the addition of Avian Influenza: The Threatening Pandemic to their offering.

The purpose of this report is to describe the threatening world pandemic caused by avian influenza, also known as bird flu. This report discusses the origins of the disease, the bird-to-human infection risks, the catastrophic health crisis avian flu poses, and the efforts by world governments and international health organizations to mitigate the impact of the threat to humans.

Chapter Titles Include:

1. Overview

2. Introduction and Executive Summary

3. The Basics of Human Influenza

4. The Basics of Avian Influenza

5. Epidemiology of Avian Influenza

6. Influenza Diagnosis & Laboratory Issues

7. Preparedness

8. Economics of Avian Influenza

9. Fighting the Flu

List of Tables

For more information visit http://www.researchandmarkets.com/reports/c41023

Contact Research and Markets Laura Wood Fax: +353 1 4100 980 press@researchandmarkets.com

The Stem Cells space is one of the hottest Areas in Biotechnology, yet
it's an Uncharted Terrain, with Significant Opportunity. This new
industry report from Select Biosciences provides an up-to-date overview
and analysis of technology, business, regulatory trends and key company
profiles.

In this report, Select Biosciences presents an analysis of the stem cell
landscape as it is maturing and evolving. A thorough overview of the
biology of stem cells is provided, together with analyses of the funding
trends, intellectual property, market opportunity, emerging areas of
application, therapeutic pipeline and key centers for stem cell research
worldwide.

Furthermore, in this report qualitative and quantitative market analysis
of the stem cells space is presented. Also presented is the potential
market opportunity, and the various qualitative and quantitative drivers
that are contributing to the growth of this marketplace.

Key Highlights of this report:

* Funding Trends in the US and Worldwide * Therapeutic Areas where Stem
Cells are expected to
have an impact, together with the clinical pipeline of
therapeutic entities
* Qualitative and quantitative market analyses * Segmentation of the
Stem Cells marketplace * Qualitative market drivers * Quantitative
market analysis * Intellectual Property (IP) landscape * Emerging market
segments

For more details visit
http://selectbiosciences.com/marketreports/stemcells2006.aspx

About Select Biosciences
www.SelectBiosciences.com

Select Biosciences Ltd. is a publisher of market reports and an
organizer of specialist biomedical meetings and training courses.

For further information on this report, contact: Kathy Gray,
Kathy.gray@selectbiosciences.com

Greystone Associates Analyzes Technology and Therapeutic Factors
(Amherst, NH) – The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative inhaler device designs - is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, a new survey reveals the emerging developments and market dynamics that have positioned dry powder inhalation as the technology of choice for an increasing number of therapeutic drugs.
The survey concludes that the rising potential of dry powder inhalation is being driven by escalating research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. “The combination of improved particle properties and more efficient inhaler designs is creating new opportunities for dry powder inhalation and expanding the range of active compounds that can be effectively delivered via the lung”, explains George Perros, Greystone’s Managing Director. “We believe dry powder inhalation will become a major factor in the delivery of a number of emerging therapeutics.”
These findings are contained in a new and comprehensive report: Dry Powder Inhalation: Drugs, Devices, And Delivery Therapeutics. It includes comprehensive assessments of dry powder inhalation technology, profiles of dry powder inhalation market participants, industry data and forecasts, and detailed analysis of design and economic factors.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org Source: Greystone Associates

This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on microplate instrumentation trends carried out in May 2005. The main survey looked at the factors that currently limit productivity from a microplate instrumentation perspective; current and future use of microplate detection instruments and microplate readouts; liquid handling for bulk reagent dispensing and sample addition; difficulty in enabling liquid handling applications and reliability of dispensing; current and future use of microplate washers and washing applications; comparative vendor use and respondent ratings; use of different microplate formats and total assay volumes; data point metrics; and microplate instrument budgets and breakdown.

Purchase report >>